Effects of Intensive Glucose Lowering in Type 2 Diabetes
Key Points
- This research aims to evaluate the effects of intensive glucose-lowering therapy on cardiovascular events in patients with type 2 diabetes and cardiovascular risks.
- Randomized trial involving 10,251 patients with a median glycated hemoglobin level of 8.1%.
- Participants received either intensive therapy targeting glycated hemoglobin <6.0% or standard therapy targeting 7.0-7.9%.
- Primary outcome assessed was the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.
- At 1 year, glycated hemoglobin levels were 6.4% in the intensive group and 7.5% in the standard group.
- Primary outcome occurred in 352 patients in the intensive group vs. 371 in the standard group (HR, 0.90; 95% CI, 0.78-1.04; P=0.16).
- Intensive therapy led to more deaths (257 vs. 203), with a hazard ratio of 1.22 (95% CI, 1.01-1.46; P=0.04).
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Randomized trial investigates intensive glucose lowering's impact on cardiovascular events in high-risk type 2 diabetes patients, revealing potential harm.
Cite This Study
Gerstein et al. (2008) studied this question.